系统性红斑狼疮患者接受生物制剂治疗时的疫苗接种策略探讨
综述探讨系统性红斑狼疮(SLE)患者接受生物制剂治疗时疫苗接种的已知证据与潜在问题。文中指出针对接受生物制剂治疗人群的疫苗免疫原性与接种方案数据相对较少,目前尚无明确的SLE疫苗接种共识。
要点
- SLE患者感染并发症与病死率相关,疫苗免疫与接种规划极为重要。
- 监测疫苗效力与免疫抑制状态下免疫应答的研究呈指数增长。
- 接受生物制剂治疗人群的疫苗接种数据相对较少,尚无明确共识。
核心结论
- 本综述旨在梳理SLE患者接受生物制剂治疗时疫苗接种的已知证据并讨论潜在问题。
- 目前尚无关于SLE患者疫苗接种政策的明确共识。
研究设计与样本
- 综述,检索与汇总SLE患者接受生物制剂治疗时疫苗接种相关的已发表研究。
主要发现
- 近年来疫苗效力监测与免疫抑制状态下免疫应答测定的研究数量呈指数增长。
- 在风湿病生物制剂时代,针对接受生物制剂治疗人群上述参数的研究数据发表相对较少。
局限性
- 接受生物制剂治疗人群的疫苗接种相关数据发表相对较少。
- 目前尚无关于SLE患者疫苗接种政策的明确共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, treat-to-target strategy and early intervention strategies with immunosuppressive agents have attempted to improve the prognosis and outcome in patients with autoimmune inflammatory rheumatic diseases. However, infectious complications due to side effects of medication remain a major concern in routine practice. In this regard, vaccine immunity and vaccination programmes are of the utmost importance in patients with systemic lupus erythematosus (SLE) in terms of morbidity and mortality. Encouragingly, research investigations have increased exponentially, both in monitoring the vaccines efficacy, and in determining the immune response while patients are on immunosuppression., However, in this biological era in rheumatology, relatively little data have been published investigating these parameters in those receiving biological agents, therefore, no definitive consensus about a vaccination policy for patients with SLE is currently available. In this review, we aim to address what is established about vaccinating patients with SLE on biological agents and discuss potential problems.
引用
- Yıldırım R, Oliveira T, Isenberg DA, et al. Approach to vaccination in systemic lupus erythematosus on biological treatment. Ann Rheum Dis. 2023. PMID: 37336639. doi:10.1136/ard-2023-224071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。